# SUTENT (SUNITINIB, SU11248)in Patients With Recurrent or Progressive Glioblastoma Multiforme

> **NCT00535379** · PHASE2 · UNKNOWN · sponsor: **Medical University Innsbruck** · enrollment: 70 (estimated)

## Conditions studied

- Glioblastoma Multiforme

## Interventions

- **DRUG:** Sunitinib

## Key facts

- **NCT ID:** NCT00535379
- **Lead sponsor:** Medical University Innsbruck
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2007-10
- **Primary completion:** 2010-12
- **Final completion:** 2011-01
- **Target enrollment:** 70 (ESTIMATED)
- **Last updated:** 2010-08-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00535379

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00535379, "SUTENT (SUNITINIB, SU11248)in Patients With Recurrent or Progressive Glioblastoma Multiforme". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT00535379. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*